HMGB1 and cancer: In line with this notion, the knockout of HMGB1 in cancer cells and the antibody-mediated neutralization of TLR4 in the host limit therapeutically relevant immune responses (and hence disease control) driven by anthracyclines, cyclophosphamide, or oxaliplatin in preclinical in vivo models103,109.